These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11796386)

  • 21. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
    Azargun R; Soroush Barhaghi MH; Samadi Kafil H; Ahangar Oskouee M; Sadeghi V; Memar MY; Ghotaslou R
    J Glob Antimicrob Resist; 2019 Jun; 17():39-43. PubMed ID: 30445211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An unusually high level of quinolone resistance associated with type II topoisomerase mutations in quinolone resistance-determining regions of Aeromonas caviae isolated from diarrhoeal patients.
    Sinha S; Chattopadhyay S; Bhattacharya SK; Nair GB; Ramamurthy T
    Res Microbiol; 2004 Dec; 155(10):827-9. PubMed ID: 15567276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes.
    Casson N; Greub G
    Int J Antimicrob Agents; 2006 Jun; 27(6):541-4. PubMed ID: 16697560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in Quinolone-resistant Shigella dysenteriae serotype 1 clinical isolates from Kolkata, India.
    Dutta S; Kawamura Y; Ezaki T; Nair GB; Iida K; Yoshida S
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1660-1. PubMed ID: 15793166
    [No Abstract]   [Full Text] [Related]  

  • 25. Mechanism of plasmid-mediated quinolone resistance.
    Tran JH; Jacoby GA
    Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5638-42. PubMed ID: 11943863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular characterization of acquired enrofloxacin resistance in Mycoplasma synoviae field isolates.
    Lysnyansky I; Gerchman I; Mikula I; Gobbo F; Catania S; Levisohn S
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3072-7. PubMed ID: 23612192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolone resistance and molecular characterization of gyrA and parC quinolone resistance-determining regions in Escherichia coli isolated from poultry.
    Vanni M; Meucci V; Tognetti R; Cagnardi P; Montesissa C; Piccirillo A; Rossi AM; Di Bello D; Intorre L
    Poult Sci; 2014 Apr; 93(4):856-63. PubMed ID: 24706962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates.
    Ribera A; Doménech-Sanchez A; Ruiz J; Benedi VJ; Jimenez de Anta MT; Vila J
    Microb Drug Resist; 2002; 8(4):245-51. PubMed ID: 12523620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.
    Ruiz J; Jurado A; Garcia-Méndez E; Marco F; Aguilar L; Jiménez de Anta MT; Vila J
    J Antimicrob Chemother; 2001 Oct; 48(4):545-8. PubMed ID: 11581235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase IV mutations in quinolone-resistant salmonellae selected in vitro.
    Hansen H; Heisig P
    Microb Drug Resist; 2003; 9(1):25-32. PubMed ID: 12705680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones.
    Bébéar CM; Renaudin H; Charron A; Clerc M; Pereyre S; Bébéar C
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3323-5. PubMed ID: 14506049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS; Yague G; Fisher LM
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.
    Bébéar CM; Renaudin H; Charron A; Bové JM; Bébéar C; Renaudin J
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2304-11. PubMed ID: 9736554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal dissemination of Yersinia enterocolitica strains with various susceptibilities to nalidixic acid.
    Sánchez-Céspedes J; Navia MM; Martínez R; Orden B; Millán R; Ruiz J; Vila J
    J Clin Microbiol; 2003 Apr; 41(4):1769-71. PubMed ID: 12682183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Investigating the fluoroquinolone molecular resistant mechanism of Stenotrophomonas maltophilia].
    Tao CM; Lü XJ; Li P
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):266-9. PubMed ID: 16608091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of gyrA and parC mutations in enterococci from environmental samples with reduced susceptibility to ciprofloxacin.
    Petersen A; Jensen LB
    FEMS Microbiol Lett; 2004 Feb; 231(1):73-6. PubMed ID: 14769469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-nucleotide polymorphism mutation spectra and resistance to quinolones in Salmonella enterica serovar Enteritidis with a mutator phenotype.
    Levy DD; Sharma B; Cebula TA
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2355-63. PubMed ID: 15215081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
    Deguchi T; Kikuchi M; Yasuda M; Ito S
    J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.